A single dose of PHA121 (PHA-022121), Pharvaris’ investigational therapy for hereditary angioedema (HAE), is safe…
Articles by Joana Carvalho, PhD
Routine injectable treatments to prevent hereditary angioedema (HAE) attacks place a large burden on patients and their caregivers, a…
The U.S. Food and Drug Administration (FDA) has extended the use of Haegarda, a C1-INH replacement medication, as…
The lack of control of a key enzyme associated with the overproduction of bradykinin seems to be the common…
Angioedema News brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important events dealing with…
KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial…
The Canadian Drug Expert Committee (CDEC) has recommended that Takhzyro (lanadelumb) be reimbursed by public drug…
The National Institute for Health and Clinical Excellence (NICE) has recommended Takhzyro (lanadelumb) as a preventive…
Prophylactic, or preventive treatment with Haegarda quickly reduced the number of attacks — sudden episodes of swelling — in…
A single dose of Ruconest (conestat alfa) was sufficient to rapidly and safely treat almost 96% of all acute…